RECRUITING Not applicable ClinicalTrials.gov

Impact of a Multidisciplinary Assessment in Day Hospitalization Versus Standard Care on the Deployment of Supportive Oncology Care Recommended by the Personalized Post-cancer Plan in Patients at the End of Initial Treatment for Gynecological Ovarian and Endometrial Cancer Endometrial Cancer

Sponsor: Centre Francois Baclesse • ClinicalTrials.gov ID: NCT06553612

Registry updated: 2026-09-24

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This project proposes a structuring of supportive oncology care for the recovery phase after gynecological cancer (ovarian/trope/peritoneum or endometrium). Patients will be divided into three groups based on the identification of oncological support care needs. Patients with supportive oncology care needs will be randomized into two groups: the experimental group, receiving a personalized post-cancer plan with a multidisciplinary assessment of supportive oncology care needs in a day hospital and coordinated follow-up by the referring study nurse, and the control group, receiving a personalized post-cancer plan without a day hospital. Randomization will be stratified according to tumor location (ovary vs. endometrium), use of supportive oncology care during treatment, and treatment center. Patients with no need for supportive oncology care will be followed in an observational cohort. The main objective is to identify and manage the supportive oncology care needs of patients in remission from endometrial or ovarian cancer to improve their quality of life and post-treatment follow-up. A medico-economic analysis will be performed.

Interventions

Multidisciplinary assessment (Other)
Delivery of a personalized post-cancer plan with multidisciplinary assessment of oncology support care needs in a day hospital
Standard assesment (Other)
Delivery of a personalized post-cancer plan without a day hospital
Observational cohort (Other)
Patients with no cancer sequelae, no adverse effects and no need for oncological support care will not be randomized, but will be followed as part of an observational cohort

Eligibility criteria

Inclusion Criteria: * Patient \> 18 years * Patients in remission from first-line treatment of endometrial or ovarian/tumor/peritoneal cancer. * Patient who has completed her initial treatment; patients on maintenance therapy are eligible. * Fluency in French * Patient with access to a telephone line * Patient affiliated to a social security scheme * Signature of informed consent prior to any specific study procedure Exclusion Criteria: * Any associated medical or psychiatric condition that could compromise the patient's ability to participate in the study * Patient with locoregional or metastatic recurrence * Patient deprived of liberty, under guardianship or curatorship * Simultaneous participation in a therapeutic clinical trial

Conditions

Gynecologic Cancer Remission

Locations

CHU, Besançon — Besançon, France
François Baclesse — Caen, France
Centre Jean Perrin — Clermont-Ferrand, France
Centre Léon Bérard — Lyon, France
Hopital Diaconesses Croix Saint-Simon — Paris, France
Hopital Europeen George Pompidou — Paris, France
Hôpital COCHIN — Paris, France
Institut Curie — Paris, France
Hopital privé des Côtes d'Armor — Plérin, France
Institut Curie, St Cloud — Saint-Cloud, France
CHU, Saint Etienne — Saint-Etienne, France
CHU — Strasbourg, France
Gustave Roussy — Villejuif, France

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment